MedPage Today on MSN

Dual Immunotherapy and Liver Perfusion Delays Progression in Uveal Melanoma

Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the ...
Seeking Alpha

iOnctura reaches new clinical milestones in uveal melanoma

Completed Phase I DIONE-01 study demonstrates clinical activity and long-term safety of roginolisib, a unique allosteric modulator of PI3Kδ Patients with uveal melanoma showed a doubling of overall ...
Nasdaq

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 December 2024) The European Organisation for Research and Treatment of Cancer (EORTC), an independent clinical cancer research ...

Delcath: Fundamentals Intact, Despite Share Price Weakness

Delcath Systems, Inc.’s Q3 revenue was pressured by weak patient starts, but 2026 growth prospects remain strong. Click for ...

IDEAYA Biosciences Teases End-of-March Data for Darovasertib Combo at Citi Oncology Summit

IDEAYA Biosciences (NASDAQ:IDYA) executives outlined multiple upcoming clinical catalysts at Citi’s 2026 Virtual Oncology ...
EurekAlert!

3D models of uveal melanoma offer hope for improved treatments

ROCHESTER, Minnesota — Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better ...
CURE

Combining Genetic Tests Offers Superior Risk Prediction in Uveal Melanoma

The study highlights that combining the DecisionDx-UM test with PRAME expression is superior to standard mutation analysis. And for a patient who's just been diagnosed with uveal melanoma, what does ...